Type 1 Diabetes Clinical Trial
Official title:
An Open-Label, Randomized, Two-Period, Crossover Study to Characterize the Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls
Verified date | December 2014 |
Source | Vanderbilt University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Intensive control of Type 1 Diabetes is critical in prevention of long term complications.
Unfortunately, there is a three-fold increase in hypoglycemia with intensive control.
Hypoglycemia is often the major limiting factor in achieving good control. Insulin treatment
of diabetes is composed of some form of short acting insulin regimen in order to provide
control of blood glucose excursions that are the result of glucose intake as well as a basal
insulin regimen either in a continuous administration (as in continuous subcutaneous insulin
infusion-"pump therapy"), once a day injection (insulin Glargine), twice a day (ultralente
or NPH or lente insulin) or a premixed version that is combined with the short acting
insulin (70/30 or 75/25). Often low blood sugars are the result of less physiologically
absorbed insulins whose peak of action is earlier or later than the peak absorption of
glucose from a meal.
Apidra (glulisine insulin) is a new short acting insulin analogue whose peak and duration of
action are ideal in that it may be administered more appropriately prior to and even after a
meal with evidence of good control of blood glucose excursions from a meal. The purpose of
this study is to compare the effect of Apidra upon meal related blood glucose profile as
compared to those treated with 70/30 insulin in patients with Type 1 Diabetes. The
investigators also will study healthy volunteers as controls who will not be treated with
insulin but will be evaluated for mealtime absorption and blood glucose profile during
similar meal intake. The investigators will use a stable isotope tritiated glucose.
Status | Completed |
Enrollment | 24 |
Est. completion date | December 2010 |
Est. primary completion date | April 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Diabetic Subjects 1. 12 adults (males or females) with Type 1 Diabetes, aged 18 to 55 years. 2. C-peptide-negative 3. Body mass index < 29.0 kg/m2 - Healthy Subjects 1. 12 non-smoking adults (males or females), aged 18 to 55 years 2. Normal response to an oral glucose tolerance test (OGTT) 3. Body mass index < 29.0 kg/m2 Exclusion Criteria: - Diabetic Subjects 1. Hemoglobin A1c >9% 2. Total daily insulin requirements >0.8 units/kg actual body weight 3. History of hypoglycemia that required the subject to see medical attention (i.e., doctor's office visit, ER visit, or EMT/paramedic attention) within 6 months of the study. 4. History of acute metabolic complications within 3 months of the study 5. History of lipodystrophy. 6. History of or suspected diabetic gastroparesis or current treatment with any drugs known to affect gastrointestinal motility. 7. Inability or unwillingness to administer subcutaneous insulin injections in the abdomen. 8. Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study. 9. Active peptic ulcer disease or a history of gastrointestinal surgery within the last 6 months years. 10. History of malignancy (except basal cell carcinoma and carcinoma in situ) within the last 5 years. 11. Pregnant or lactating females or females of childbearing potential who are unwilling to abstain from sexual intercourse or use reliable, medically accepted methods of contraception. 12. History of alcoholism or drug abuse within 12 months of the study. 13. Is the investigator, sub-investigator, research assistant, pharmacist, study coordinator, other study staff, or relative thereof directly involved in the conduct of this protocol. - Healthy Subjects 1. Hemoglobin A1c >6.0% 2. Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study. 3. Historical, clinical, or laboratory evidence of liver disease including but not limited to transaminase activity concentrations >2.5 times the upper limit of the reference range. 4. Current treatment with any drugs known to affect gastrointestinal motility. 5. Active peptic ulcer disease or a history of gastrointestinal surgery within the last 6 months. 6. History of malignancy (except basal cell carcinoma and carcinoma in situ) within the last 5 years. 7. Pregnant or lactating females or females of childbearing potential who are unwilling to abstain from sexual intercourse or use reliable, medically accepted methods of contraception. 8. History of alcoholism or drug abuse within 12 months of the study. 9. Is the investigator, sub-investigator, research assistant, pharmacist, study coordinator, other study staff, or relative thereof directly involved in the conduct of this protocol. |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University | Sanofi |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Insulin levels | 24 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |